PHIO
Healthcare BiotechnologyPhio Pharmaceuticals Corp.
$0.99
-0.03 -3.43% today
Price History
Not enough data
Key Stats
Market Cap
11.44M
Avg Volume
586,787
EPS
-$1.29
52W High
$4.19
52W Low
$0.81
Div. Yield
0.0%
Analyst Ratings
Buy0
Str Buy
1
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-1.61
P/B Ratio
0.91
EV/EBITDA
0.12
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(113.7%)
Return on Assets
(65.8%)
Liquidity & Leverage
Current Ratio
8.39
Quick Ratio
7.62
Total Cash
13.00M
Total Debt
0
About
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
phiopharma.com